Profile data is unavailable for this security.
About the company
Mayinglong Pharmaceutical Group Co., Ltd. is a China-based company, principally engaged in pharmaceutical production, retailing and wholesaling businesses. The Company's pharmaceutical products are classified as drugs for hemorrhoid, including diosmin tablets, suppositories, pastes and granules, among others; drugs for cough, including levodropropizine oral solution and compound glycyrrhiza oral solution, as well as drugs for skin injuries, including products such as erythromycin ointment. The Company also provides specialty drugs. The Company is also engaged in the production and distribution of eye cream products with the brand named Mayinglong BaBao, as well as the provision of hospital clinical service. The Company distributes its products mainly in domestic markets.
- Revenue in CNY (TTM)3.48bn
- Net income in CNY482.37m
- Incorporated1994
- Employees2.88k
- LocationMayinglong Pharmaceutical Group Co LtdNo. 100, Nanhu Zhoujiawan, WuchangWUHAN 430064ChinaCHN
- Phone+86 2 787291519
- Fax+86 2 787291724
- Websitehttp://www.mayinglong.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Changchun BCHT Biotechnology Co | 1.61bn | 414.29m | 10.73bn | 1.24k | 25.92 | 2.56 | -- | 6.68 | 1.00 | 1.00 | 3.88 | 10.15 | 0.3181 | 1.00 | 1.06 | 1,295,333.00 | 8.20 | 9.95 | 10.23 | 12.81 | 87.55 | 86.63 | 25.77 | 24.03 | 1.85 | -- | 0.0147 | 10.55 | 70.30 | 12.36 | 175.98 | 31.37 | 21.04 | -- |
| Guobang Pharma Ltd | 5.71bn | 702.28m | 10.86bn | 4.23k | 15.42 | 1.39 | -- | 1.90 | 1.26 | 1.26 | 10.26 | 14.03 | 0.5599 | 3.29 | 7.84 | 1,350,536.00 | 6.87 | 10.36 | 8.88 | 14.24 | 23.87 | 27.49 | 12.27 | 15.01 | 1.70 | -- | 0.1992 | 18.24 | -6.49 | 10.28 | -33.49 | 23.77 | 35.60 | -- |
| Jiangsu Sinopep Allsin Bphrmctcl Co Ltd | 1.58bn | 421.47m | 10.90bn | 1.55k | 26.32 | 4.17 | -- | 6.92 | 1.88 | 1.88 | 7.14 | 11.91 | 0.4286 | 1.19 | 3.67 | 1,020,281.00 | 11.58 | 5.86 | 16.99 | 7.59 | 67.12 | 55.41 | 27.01 | 17.20 | 0.912 | 24.02 | 0.3477 | 27.59 | 58.69 | 32.24 | 26.20 | 29.99 | 27.32 | -- |
| Heilongjiang ZBD Pharmaceutical Co Ltd | 2.58bn | 114.60m | 10.94bn | 2.55k | 97.34 | 1.41 | -- | 4.24 | 0.1194 | 0.1194 | 2.74 | 8.24 | 0.2118 | 1.48 | 0.7645 | 1,014,704.00 | 0.8822 | 3.48 | 1.17 | 4.78 | 34.52 | 38.93 | 4.17 | 10.08 | 2.23 | -- | 0.2888 | 27.18 | -25.50 | 2.45 | 155.00 | 0.4417 | -25.68 | 4.05 |
| Chongqing Genrix Biophrmctcl Co Ltd | 13.56m | -779.42m | 11.03bn | 547.00 | -- | 4.69 | -- | 813.12 | -2.13 | -2.13 | 0.037 | 6.42 | 0.0039 | 0.1009 | 1.37 | 24,790.27 | -22.22 | -- | -23.06 | -- | 55.87 | -- | -5,747.82 | -- | 18.62 | -- | 0.2454 | -- | 154.92 | -- | -39.03 | -- | -- | -- |
| Mayinglong Pharmaceutical Group Co Ltd | 3.48bn | 482.37m | 11.04bn | 2.88k | 22.89 | 2.76 | -- | 3.17 | 1.12 | 1.12 | 8.08 | 9.28 | 0.6872 | 6.42 | 8.53 | 1,208,299.00 | 9.74 | 10.82 | 11.64 | 13.47 | 44.84 | 41.18 | 14.17 | 14.08 | 4.40 | -- | 0.0936 | 33.04 | -11.20 | 7.38 | -7.46 | 20.26 | 58.33 | 21.67 |
| Liaoning Chengda Biotechnology Co Ltd | 1.72bn | 332.10m | 11.34bn | 1.73k | 33.90 | 1.19 | -- | 6.60 | 0.8032 | 0.8032 | 4.16 | 22.93 | 0.1702 | 0.763 | 1.43 | 991,973.80 | 3.29 | 10.63 | 3.41 | 11.01 | 80.53 | 85.74 | 19.33 | 39.56 | 17.44 | -- | 0.0018 | 31.53 | -3.58 | 4.71 | -34.75 | -5.56 | 39.78 | -- |
| Jiangxi Tianxin Pharmaceutical Co Ltd | 2.01bn | 557.43m | 11.45bn | 2.47k | 20.55 | 2.57 | -- | 5.70 | 1.27 | 1.27 | 4.58 | 10.18 | 0.3977 | 2.75 | 10.26 | 812,720.60 | 11.04 | -- | 11.82 | -- | 41.64 | -- | 27.76 | -- | 6.39 | -- | 0.0234 | -- | -18.34 | -- | -23.51 | -- | -- | -- |
| KPC Pharmaceuticals Inc | 7.55bn | 446.07m | 11.53bn | 5.05k | 25.71 | 2.08 | -- | 1.53 | 0.5924 | 0.5924 | 10.03 | 7.31 | 0.7819 | 2.75 | 2.56 | 1,494,697.00 | 4.64 | 5.42 | 7.75 | 9.13 | 40.84 | 43.68 | 5.94 | 5.70 | 1.51 | -- | 0.172 | 35.75 | -6.99 | 1.64 | 16.05 | 5.79 | -21.33 | 14.87 |
Data as of Sep 13 2024. Currency figures normalised to Mayinglong Pharmaceutical Group Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
18.49%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Bank of Communications Schroder Fund Management Co., Ltd.as of 30 Jun 2024 | 24.54m | 5.70% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2024 | 12.06m | 2.80% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2024 | 8.63m | 2.01% |
| Rongtong Fund Management Co., Ltd.as of 30 Jun 2024 | 7.49m | 1.74% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 7.03m | 1.63% |
| Bank of China Investment Management Co., Ltd.as of 30 Jun 2024 | 6.99m | 1.62% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024 | 4.24m | 0.98% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2024 | 4.08m | 0.95% |
| UBS Asset Management (Hong Kong) Ltd.as of 27 Sep 2024 | 2.37m | 0.55% |
| First Seafront Fund Management Co., Ltd.as of 30 Jun 2024 | 2.13m | 0.49% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
